![Joshua Cohen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Joshua Cohen has founded a company called Haystack Oncology, Inc. in 2021 and currently holds the title of Chief Innovation Officer.
Aktive Positionen von Joshua Cohen
Unternehmen | Position | Beginn |
---|---|---|
Haystack Oncology, Inc.
![]() Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Gründer | 01.01.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Haystack Oncology, Inc.
![]() Haystack Oncology, Inc. Medical/Nursing ServicesHealth Services Part of Quest Diagnostics, Inc., Haystack Oncology, Inc. is a biopharmaceutical company based in Baltimore, MD. The Haystack MRD test is CLIA certified in the US and is available for biopharmaceutical clinical development in laboratories located in various locations. The company developed Haystack MRD™, a next-generation tumor-informed approach for the measurement of minimal residual disease. Haystack Oncology works with biopharmaceutical companies to advance important therapeutics to markets, from early phase clinical development to companion diagnostics. The test accelerates clinical development with better MRD testing unmatched sensitivity and specificity for confident MRD detection. The company leverages unmatched sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development. The company was founded in 2021 by Kenneth W. Kinzler, Nickolas Papadopoulos, Joshua Cohen, Bert Vogelstein, and the CEO is Dan Edelstein. Haystack Oncology was acquired by Quest Diagnostics, Inc. on June 21, 2023 for $450 million. | Health Services |